CSIMarket
 


Novabay Pharmaceuticals Inc   (NBY)
Other Ticker:  
 
 

NBY's Revenue Growth by Quarter and Year

Novabay Pharmaceuticals Inc 's Revenue results by quarter and year




NBY Revenue (in millions $) FY 2023 FY 2022 FY 2021 FY 2020
IV Quarter December - 3.38 1.84 2.17
III Quarter September 2.84 2.55 2.13 3.98
II Quarter June 4.31 2.52 1.81 1.89
I Quarter March 4.28 2.64 1.89 1.70
FY   11.43 11.09 7.67 9.74



NBY Revenue third quarter 2023 Y/Y Growth Comment
Novabay Pharmaceuticals Inc reported Revenue increase of 11.29% year on year in the third quarter 2023, to $ 2.84 millions, this is lower than Novabay Pharmaceuticals Inc 's recent average Revenue rise of 86.06%.

Looking into third quarter 2023 results within Major Pharmaceutical Preparations industry 89 other companies have achieved higher Revenue growth. While Novabay Pharmaceuticals Inc ' s Revenue growth of 11.29% ranks overall at the positon no. 877 in the third quarter 2023.




NBY Revenue ( Y/Y Growth %) 2023
2022 2021 2020
IV Quarter December - 83.7 % -15.21 % 33.95 %
III Quarter September 11.29 % 19.72 % -46.48 % 122.35 %
II Quarter June 71.03 % 39.23 % -4.23 % 26.85 %
I Quarter March 62.12 % 39.68 % 11.18 % -53.17 %
FY   - 44.59 % -21.25 % 14.19 %

Financial Statements
Novabay Pharmaceuticals Inc 's third quarter 2023 Revenue $ 2.84 millions NBY's Income Statement
Novabay Pharmaceuticals Inc 's third quarter 2022 Revenue $ 2.55 millions Quarterly NBY's Income Statement
New: More NBY's historic Revenue Growth >>


NBY Revenue (Quarter on Quarter Growth %)

2023
2022 2021 2020
IV Quarter December - 32.55 % -13.62 % -45.48 %
III Quarter September -34.15 % 1.19 % 17.68 % 110.58 %
II Quarter June 0.7 % -4.55 % -4.23 % 11.18 %
I Quarter March 26.63 % 43.48 % -12.9 % 4.94 %
FY (Year on Year)   - 44.59 % -21.25 % 14.19 %




Revenue third quarter 2023 Y/Y Growth Company Ranking
Within: No.
Major Pharmaceutical Preparations Industry #90
Healthcare Sector #204
Overall #877

Revenue Y/Y Growth Statistics
High Average Low
1815.82 % 86.06 % -130.73 %
(March 31, 2016)   (Sep. 30, 2014)
Revenue third quarter 2023 Y/Y Growth Company Ranking
Within: No.
Major Pharmaceutical Preparations Industry #90
Healthcare Sector #204
Overall #877
Revenue Y/Y Growth Statistics
High Average Low
1815.82 % 86.06 % -130.73 %
(March 31, 2016)   (Sep. 30, 2014)

Revenue by Quarter for the Fiscal Years 2020, 2021, 2022, 2023

Novabay Pharmaceuticals Inc 's Q/Q Revenue Growth


Revenue Q/Q Growth Statistics
High Average Low
2091.3 % 65.14 % -69.41 %
(Jun 30 2015)  


NBY's III. Quarter Q/Q Revenue Comment
In the III. Quarter 2023 Novabay Pharmaceuticals Inc realized fall in Revenue sequentially by -34.15% to $ 2.84 millions, from $ 4.31 millions achived in the previous reporting period.

Those cyclical factors which normally energize III. Quarter 2023 performance, could not salvage the III. Quarter for the Novabay Pharmaceuticals Inc , Daniel Muņoz, Healthcare sector consultant said, he mentioned some skepticism conserning Novabay Pharmaceuticals Inc 's direction, he identified additional difficulties down the road for NBY and wrote that average sequential Revenue growth is at 65.14% for NBY.

Within Major Pharmaceutical Preparations industry 190 other companies have achieved higher Revenue quarter on quarter growth. While Novabay Pharmaceuticals Inc 's Revenue growth quarter on quarter, overall rank is 3246.


Revenue Q/Q Growth Company Ranking
Within: No.
Major Pharmaceutical Preparations Industry #191
Healthcare Sector #512
Overall #3246
Revenue Q/Q Growth Company Ranking
Within: No.
Major Pharmaceutical Preparations Industry #191
Healthcare Sector #512
Overall #3246
Revenue Q/Q Growth Statistics
High Average Low
2091.3 % 65.14 % -69.41 %
(Jun 30 2015)  


NBY's III. Quarter Q/Q Revenue Comment
In the III. Quarter 2023 Novabay Pharmaceuticals Inc reported fall in Revenue sequentially by -34.15% to $ 2.84 millions, from $ 4.31 millions released in the previous quarter.

Some periodic influence were not able to recover the III. Quarter for the Novabay Pharmaceuticals Inc , Daniel Muņoz, Healthcare sector consultant pointed out, he voiced little pessimism for the Novabay Pharmaceuticals Inc 's direction.

Within Major Pharmaceutical Preparations industry 190 other companies have achieved higher Revenue quarter on quarter growth. While Novabay Pharmaceuticals Inc 's Revenue growth quarter on quarter, overall rank is 3246.


Novabay Pharmaceuticals Inc 's 12 Months Revenue Growth Year on Year


Revenue TTM Growth

12 Months Ending
(Sep 30 2023)
12 Months Ending
(Jun 30 2023)
12 Months Ending
(Dec 31 2022)
12 Months Ending
(Dec 31 2022)
12 Months Ending
(Sep 30 2022)
Cumulative Revenue 12 Months Ending $ 14.80 $ 14.51 $ 12.72 $ 12.72 $ 11.08
Y / Y Revenue Growth (TTM) 55.02 % 58.95 % 51.07 % 51.07 % 44.52 %
Year on Year Revenue Growth Overall Ranking # 356 # 1617 # 0 # 3087 # 482
Seqeuential Revenue Change (TTM) 1.98 % 14.07 % 14.8 % 14.8 % 16.08 %
Seq. Revenue Growth (TTM) Overall Ranking # 877 # 2751 # 0 # 1831 # 293




Cumulative Revenue growth Comment
With the quarterly Revenue reported in the Sep 30 2023 period, Novabay Pharmaceuticals Inc 's cumulative twelve months Revenue were $ 15 millions, company would post below average annual Revenue growth of 16.08% year on year, if the fiscal year would end at Sep 30 2023.
A slow-down in the Novabay Pharmaceuticals Inc 's Revenue growth from the 4.31% growth in Jun 30 2023.

In the Healthcare sector 118 other companies have achieved higher trailing twelve month Revenue growth. While Total ranking has impoved so far to 356, from total ranking in previous quarter at 1617.

Revenue TTM Q/Q Growth Statistics
High Average Low
1815.82 %
86.06 %
-130.73 %
 

Revenue TTM Y/Y Growth Company Ranking
Within: No.
Major Pharmaceutical Preparations Industry # 90
Healthcare Sector # 119
Overall # 356

Revenue TTM Y/Y Growth Statistics
High Average Low
1815.82 %
86.06 %
-130.73 %
 


Revenue TTM Q/Q Growth Company Ranking
Within: No.
Industry # 90
Sector # 204
S&P 500 # 877
Cumulative Revenue growth Comment
With the quarterly Revenue reported in the Sep 30 2023 period, Novabay Pharmaceuticals Inc 's cumulative twelve months Revenue were $ 15 millions, company would post below average annual Revenue growth of -130.73% year on year, if the fiscal year would end at Sep 30 2023.
A slow-down in the Novabay Pharmaceuticals Inc 's Revenue growth from the 4.31% growth in Jun 30 2023.

In the Healthcare sector 118 other companies have achieved higher trailing twelve month Revenue growth. While Total ranking has impoved so far to 356, from total ranking in previous quarter at 1617.

Revenue TTM Q/Q Growth Statistics
High Average Low
1815.82 %
86.06 %
-130.73 %
 


Revenue TTM Y/Y Growth Company Ranking
Within: No.
Major Pharmaceutical Preparations Industry # 90
Healthcare Sector # 119
Overall # 356

Revenue TTM Y/Y Growth Statistics
High Average Low
1815.82 %
86.06 %
-130.73 %
 


Revenue TTM Q/Q Growth Company Ranking
Within: No.
Industry # 90
Sector # 204
S&P 500 # 877




Other Revenue Growth
Major Pharmaceutical Preparations Industry Revenue Growth Trends and Statistics
Healthcare Sector Revenue Growth Statistics
Revenue Growth Trends for overall market
NBY's Revenue Growth Ratio versus Major Pharmaceutical Preparations Industry, Healthcare Sector and total Market
Highest Ranking Revenue Growth
Lowest Ranking Revenue Growth
Revenue Growth for NBY's Competitors
Revenue Growth for Novabay Pharmaceuticals Inc 's Suppliers
Revenue Growth for NBY's Customers

You may also want to know
NBY's Annual Growth Rates NBY's Profitability Ratios NBY's Asset Turnover Ratio NBY's Dividend Growth
NBY's Roe NBY's Valuation Ratios NBY's Financial Strength Ratios NBY's Dividend Payout Ratio
NBY's Roa NBY's Inventory Turnover Ratio NBY's Growth Rates NBY's Dividend Comparisons



Companies with similar Revenue fall for the quarter ending Sep 30 2023 within Healthcare SectorY/Y Change %Revenue for the quarter ending Sep 30 2023
Bolt Biotherapeutics Inc 19.70%$ 19.697 millions
Mimedx Group Inc 19.55%$ 19.550 millions
Veracyte inc 19.20%$ 19.203 millions
Silk Road Medical Inc 18.76%$ 18.759 millions
Werewolf Therapeutics Inc 18.65%$ 18.652 millions
Quanterix Corp18.65%$ 18.652 millions
Cano Health Inc 18.50%$ 18.502 millions
The Pennant Group Inc 18.46%$ 18.455 millions
Vericel Corporation18.24%$ 18.236 millions
United Therapeutics Corporation18.10%$ 18.101 millions
Integer Holdings Corporation18.06%$ 18.056 millions
Guardion Health Sciences Inc 17.82%$ 17.818 millions
Heron Therapeutics Inc 17.58%$ 17.581 millions
Atricure Inc 17.57%$ 17.566 millions
10x Genomics Inc 17.47%$ 17.471 millions
Sonnet Biotherapeutics Holdings Inc 17.44%$ 17.445 millions
Sanara Medtech Inc 17.09%$ 17.088 millions
Infusystem Holdings Inc16.97%$ 16.973 millions
Msa Safety Incorporated16.88%$ 16.876 millions
Twist Bioscience Corporation16.82%$ 16.820 millions
Lftd Partners Inc 16.63%$ 16.632 millions
Cytek Biosciences Inc 16.56%$ 16.555 millions
Bruker Corporation16.26%$ 16.262 millions
Liquidia Corporation16.21%$ 16.209 millions
Semler Scientific Inc 16.15%$ 16.153 millions
P3 Health Partners Inc 16.15%$ 16.149 millions
International Stem Cell Corporation15.85%$ 15.854 millions
Resmed Inc 15.80%$ 15.800 millions
Electromedical Technologies Inc15.76%$ 15.762 millions
Electromed Inc 15.63%$ 15.631 millions




Help

About us

Advertise

CSIMarket Company, Sector, Industry, Market Analysis, Stock Quotes, Earnings, Economy, News and Research. 
   Copyright Š 2024 CSIMarket, Inc. All rights reserved. This site uses cookies to make your browsing experince better. By using this site, you agree to the Terms of Service and Privacy Policy - UPDATED (Read about our Privacy Policy)

Intraday data delayed per exchange requirements. All quotes are in local exchange time. Intraday data delayed 15 minutes for Nasdaq, and other exchanges. Fundamental and financial data for Stocks, Sector, Industry, and Economic Indicators provided by CSIMarket.com